Assessment of cholesterol absorption inhibitors nanostructured aluminosilicate and cholestyramine using in vitro lipolysis model

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 291-300

  Gershkovich, Pavel ^a   Sivak, Olena ^a   Contreras Whitney, Susana ^a   Darlington, Jerald W ^b   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Technical Center   (United States)

Author keywords

Atherosclerosis; Bile acids; Intestinal absorption; Intestinal processing; Mixed micelles; Pancreatic lipase; Triglyceride

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID; BILE SALT; COLESTYRAMINE; NANOSTRUCTURED ALUMINOSILICATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; IN VITRO STUDY; INTESTINE ABSORPTION; LIPID ABSORPTION; LIPOLYSIS; NONHUMAN; RAT;

EID: 82255192508     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22770     Document Type: Article

References (29)

1. Wang DQ. 2007. Regulation of intestinal cholesterol absorption. Annu Rev Physiol 69:221-248.
2. Harper CR, Jacobson TA. 2007. The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr Opin Lipidol 18(4):401-408.
3. Davidson MH, Robinson JG. 2007. Safety of aggressive lipid management. J Am Coll Cardiol 49(17):1753-1762.
4. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. 2006. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 114(25):2788-2797.
5. Kruit JK, Groen AK, van Berkel TJ, Kuipers F. 2006. Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 12(40):6429-6439.
6. Santosa S, Varady KA, AbuMweis S, Jones PJ. 2007. Physiological and therapeutic factors affecting cholesterol metabolism: Does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci 80(6):505-514.
7. Huff MW, Pollex RL, Hegele RA. 2006. NPC1L1: Evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 26(11):2433-2438.
8. Patel SB. 2004. Ezetimibe: A novel cholesterol-lowering agent that highlights novel physiologic pathways. Curr Cardiol Rep 6(6):439-442.
9. Mel'nikov SM, Seijen ten Hoorn JW, Eijkelenboom AP. 2004. Effect of phytosterols and phytostanols on the solubilization of cholesterol by dietary mixed micelles: An in vitro study. Chem Phys Lipids 127(2):121-141.
10. Insull W Jr. 2006. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. South Med J 99(3):257-273.
11. Gershkovich P, Darlington J, Sivak O, Constantinides PP, Wasan KM. 2009. Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds. J Pharm Sci 98(7):2390-2400.
12. Sivak O, Darlington J, Gershkovich P, Constantinides PP, Wasan KM. 2009. Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet. Lipids Health Dis 8:30.
13. Zangenberg NH, Mullertz A, Kristensen HG, Hovgaard L. 2001. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J Pharm Sci 14(3):237-244.
14. Sek L, Porter CJ, Charman WN. 2001. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. J Pharm Biomed Anal 25(3, 4):651-661.
15. Sek L, Porter CJ, Kaukonen AM, Charman WN. 2002. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol 54(1):29-41.
16. Dahan A, Hoffman A. 2006. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res 23(9):2165-2174.
17. Larsen A, Holm R, Pedersen ML, Mullertz A. 2008. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: In vivo bioavailability and dynamic in vitro lipolysis. Pharm Res 25(12):2769-2777.
18. Dahan A, Hoffman A. 2008. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 129(1):1-10.
19. Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades T, Mullertz A. 2010. Precipitation of a poorly soluble model drug during in vitro lipolysis: Characterization and dissolution of the precipitate. J Pharm Sci 99(12):4982-4991.
20. Carey MC, Small DM, Bliss CM. 1983. Lipid digestion and absorption. Annu Rev Physiol 45:651-677.
21. Porter CJ, Charman WN. 2001. Intestinal lymphatic drug transport: An update. Adv Drug Deliv Rev 50(1-2):61-80.
22. Nordskog BK, Phan CT, Nutting DF, Tso P. 2001. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev 50(1, 2):21-44.
23. Phan CT, Tso P. 2001. Intestinal lipid absorption and transport. Front Biosci 6:D299-D319.
24. Lecerf JM, de Lorgeril M. 2011. Dietary cholesterol: From physiology to cardiovascular risk. Br J Nutr 106 (1):6-14.
25. Ljusberg-Wahren H, Seier Nielsen F, Brogard M, Troedsson E, Mullertz A. 2005. Enzymatic characterization of lipid-based drug delivery systems. Int J Pharm 298(2):328-332.
26. McConnell EL, Basit AW, Murdan S. 2008. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 60(1):63-70.
27. Bosner MS, Lange LG, Stenson WF, Ostlund RE Jr. 1999. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 40(2):302-308.
28. Patton JS, Carey MC. 1981. Inhibition of human pancreatic lipase-colipase activity by mixed bile salt-phospholipid micelles. Am J Physiol 241(4):G328-G336.
29. Larsson A, Erlanson-Albertsson C. 1983. The importance of bile salt for the reactivation of pancreatic lipase by colipase. Biochim Biophys Acta 750(1):171-177.